WASHINGTON — President Trump’s plan to let states and drug wholesalers import medicines from Canada doesn’t apply to every single drug in the same way — and early indications suggest some drug makers have far more to lose than others.

On Wednesday, the Trump administration began a long, regulatory march toward eventually allowing states to import drugs from Canada. While the implementation of that policy is likely to take months, if not years, four states have already passed laws directing their state administrations to submit importation plans to HHS for eventual approval. One state, Florida, has already submitted a plan, and Colorado released an early draft of its plan last month.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy